Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents

Overview of attention for article published in Journal of Clinical Oncology, March 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (93rd percentile)
Above-average Attention Score compared to outputs of the same age and source (61st percentile)

Mentioned by

news: 1 news outlet
twitter: 20 X users
patent: 3 patents

facebook: 1 Facebook page
guideline: 3 clinical guideline sources

Readers on

mendeley: 106 Mendeley

So far, Altmetric has seen 22 X posts from 20 X users, with an upper bound of 113,381 followers.

Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of… https://t.co/kF1VlvffmH

Natural history of MDS after ESA failure. I think this is poor paper that can lead towards wrong approach. The... https://t.co/cOrKxrYjBo

RT @bloodworkapp: #MDS How to treat low risk disease after #rhEpo fails? @JCO_ASCO article gives some insight. https://t.co/fvf8KhI6Nv

#MDS How to treat low risk disease after #rhEpo fails? @JCO_ASCO article gives some insight. https://t.co/fvf8KhI6Nv

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 18 additional X posts.